These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 15884662)

  • 1. Management of renal osteodystrophy in children.
    Tasic V
    Turk J Pediatr; 2005; 47 Suppl():13-8. PubMed ID: 15884662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
    Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
    Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease.
    Sanchez CP
    Semin Nephrol; 2001 Sep; 21(5):441-50. PubMed ID: 11559885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy.
    Hernandez JD; Wesseling K; Salusky IB
    Semin Dial; 2005; 18(4):290-5. PubMed ID: 16076350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of treatment of renal osteodystrophy on bone histology.
    Malluche HH; Mawad H; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of renal osteopathy in patients with chronic dialysis].
    Kiss D; Brunner FP
    Schweiz Med Wochenschr; 1996 Oct; 126(42):1792-8. PubMed ID: 8966512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.
    Sanchez CP
    Paediatr Drugs; 2003; 5(11):763-76. PubMed ID: 14580225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets.
    Pettifor JM
    Bone Miner; 1990 Jun; 9(3):199-214. PubMed ID: 2163713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
    Malluche HH; Monier-Faugere MC
    Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Markers of calcium--phosphate metabolism and bones alterations in long term kidney transplant patients].
    Spiechowicz U; Kokot F; Wiecek A
    Przegl Lek; 2003; 60(11):690-4. PubMed ID: 15058034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to minimize bone disease in renal failure.
    Martin KJ; González EA
    Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caring for chronic kidney disease patients: focus on mineral and bone disorders.
    Nguyen TV; Filson J
    Consult Pharm; 2009 Feb; 24(2):146-52. PubMed ID: 19275456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.